Results 121 to 130 of about 39,109 (309)

Phytoplankton periodicity: its motivation, mechanisms and manipulation [PDF]

open access: yes, 1982
This review summarizes some recent work to find a generalized explanation of phytoplankton periodicity in lakes. Much of the observational and experimental evidence is drawn from work centred on the large enclosures (Lund Tubes) installed in Blelham Tarn,
Reynolds, C.S.
core  

Feedback control of excitability and high K+ induced epileptiform bursts in male rat hippocampal slices with a photocaged adenosine A1 receptor agonist

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Adenosine is a potent regulator of neurotransmission and neuronal excitability, through activation of Gi coupled adenosine A1 receptors (A1Rs). Adenosine has gained interest as an anticonvulsant because of its endogenous involvement in ending seizure activity, but peripheral side effects require local application.
Erine Craey   +8 more
wiley   +1 more source

Speed Regulation of a Permanent Magnet DC Motor with Sliding Mode Control Based on Washout Filter [PDF]

open access: gold, 2022
Hugo Velasco-Muñoz   +3 more
openalex   +1 more source

Growth and shear loss characteristics of an aerobic biofilm : a thesis submitted in partial fulfilment of the requirements for the degree of Master of Technology in Biotechnology at Massey University [PDF]

open access: yes, 1990
The application of biofilms in fermentation and waste treatment processes has been increasingly considered in recent years due to several inherent advantages over suspended growth systems.
See, Tiam Teng
core  

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki   +4 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Application of fuzzy logic to power system stabilizer [PDF]

open access: yes, 2008
Power systems stability is a complex problem which was first recognised in 1920 and has been widely investigated by power system engineers ever since.
Abdullah, Shahrum Shah
core  

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata   +3 more
wiley   +1 more source

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for post‐bariatric hypoglycaemia (PBH) are empirical. We aimed to investigate the efficacy and safety of acarbose and canagliflozin for the treatment of PBH. Materials and Methods We performed a randomised, double‐blinded, cross‐over, placebo‐controlled clinical trial where placebo, acarbose 50 mg thrice daily, and ...
Carolina B. Lobato   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy